Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4550 - Molecular screening in advanced cancer patients with head and neck cancers: a retrospective analysis of MOSCATO-01 trial.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Aline Houessinon

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

A. Houessinon1, L. Verlingue1, A. Hollebecque1, C. Even2, L. Lacroix3, S. Postel-Vinay1, A. Varga1, Y. El Dakdouki1, R. Balheda1, J. Michot4, A. Gazzah1, A. Marabelle1, S. Michiels5, E. Rouleau6, I. Breuskin2, T. de Baere7, E. Angevin1, J. Scoazec8, J. Soria1, C. Massard1

Author affiliations

  • 1 Drug Development Department (ditep), Gustave Roussy, 94800 - VILLEJUIF/FR
  • 2 Department Of Head And Neck Surgical & Medical Oncology, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 3 Biology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4 Drug Development Department, Gustave Roussy, 94800 - VILLEJUIF/FR
  • 5 Biostatistics And Epidemiology, Gustave Roussy, Université Paris-Saclay, 94800 - Villejuif/FR
  • 6 Department Of Medical Biology And Pathology, Laboratory Of Translational Research And Biological Resource Center, Ammica, Inserm Us23/cnrs Ums3655, Gustave Roussy, University Paris-Saclay, 94800 - Villejuif/FR
  • 7 Radiation oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 8 Pathology, Laboratory Of Translational Research And Biological Resource Center, Ammica, Inserm Us23/cnrs Ums3655, Gustave Roussy, University Paris-Saclay, 94800 - Villejuif/FR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4550

Background

Advanced and metastatic head and neck (HN) cancers are a heterogeneous tumour with poor outcome as few therapeutic options are available. Until now, no accepted genomic profiles can lead to an oriented treatment. We performed a retrospective analysis of the MOSCATO-01 trial for patients with advanced and metastatic HN cancer.

Methods

Patients included in MOSCATO-01 trial underwent biopsies for molecular screening analyses by Comparative Genomic Hybridisation Array, Next Generation Sequencing or RNA Seq. Patients were treated by targeted treatment on the molecular alteration screening. Progression-free survival (PFS) ratio was the primary endpoint corresponding to PFS2/PFS1 (PFS2: PFS in patients treated according to molecular alteration; PFS1: PFS in patients treated with usual treatment).

Results

129 patients (12.4%) with advanced or metastatic HN cancers were included in MOSCATO-01 trial among 1035 patients. The most frequent histologic type was squamous cell carcinoma (62.7%), followed by adenocarcinoma and kystic adenoid carcinoma (6.5% each) and muco epidermoid carcinoma (3.7%). Patients were in most of the cases heavily pre-treated, as 65% of them received 3 lines of prior systemic treatment. More than 60% of the patients had a RMH score at 0. Of 107 patients (82.9%) who underwent a biopsy, 45 (42%) presented potential targetable molecular alterations: PI3KCA, ERBB2, NOTCH and MET where the most frequent targeted molecular alterations. Moreover, 33.3% of them (n = 15) had a targeted treatment: 9 patients in phase 1 trial and 6 with off label use therapeutic. The median progression free survival of the 15 patients treated according to molecular alteration was 1.7 months [0.26-6.93]. The PFS ratio was above 1.3 for 46% of the patients.

Conclusions

MOSCATO-01 for HN cancers showed that a large proportion of patients have cancer with actionable molecular alteration, with benefit on PFS ratio of oriented treatment guided by molecular screening. Precision medicine in advanced HN cancers could bring new therapeutic options in these hard to treat cancers.

Clinical trial identification

Legal entity responsible for the study

Christophe Massard.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.